The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE).


Journal

Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306

Informations de publication

Date de publication:
25 07 2020
Historique:
received: 17 01 2020
accepted: 24 06 2020
pubmed: 28 7 2020
medline: 28 9 2021
entrez: 26 7 2020
Statut: epublish

Résumé

To ensure that clinical laboratories produce results that are both accurate and of clinical utility it is essential that only samples of adequate quality are analysed. Although various studies and databases assessing the stability of analytes in different settings do exist, guidance on how to perform and report stability studies is lacking. This results in studies that often do not report essential information, thus compromising transferability of the data. The aim of this manuscript is to describe the Checklist for Reporting Stability Studies (CRESS) against which future studies should be reported to ensure standardisation of reporting and easy assessment of transferability of studies to other healthcare settings. The EFLM WG-PRE (European Federation of Clinical Chemistry and Laboratory Medicine Working Group for the Preanalytical Phase) produced the CRESS checklist following a detailed literature review and extensive discussions resulting in consensus agreement. The checklist consists of 20 items covering all the aspects that should be considered when producing a report on a stability study including details of what should be included for each item and a rationale as to why. Adherence to the CRESS checklist will ensure that studies are reported in a transparent and replicable way. This will allow other laboratories to assess whether published data meet the stability criteria required in their own particular healthcare scenario. The EFLM WG-PRE encourage researchers and authors to use the CRESS checklist as a guide to planning stability studies and to produce standardised reporting of future stability studies.

Identifiants

pubmed: 32710715
doi: 10.1515/cclm-2020-0061
pii: cclm-2020-0061
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-69

Auteurs

Michael Cornes (M)

Clinical Chemistry Department, Worcester Acute Hospitals NHS Trust, Worcester, UK.

Ana-Maria Simundic (AM)

Department for Medical Laboratory Diagnostics, Clinical Hospital "Sveti Duh"; Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.

Janne Cadamuro (J)

Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.

Seán J Costelloe (SJ)

Department of Clinical Biochemistry, Cork University Hospital, Wilton, Cork, Republic of Ireland.

Geoffrey Baird (G)

Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.

Gunn B B Kristensen (GBB)

Norwegian Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway.

Alexander von Meyer (A)

Institute for Laboratory Medicine and Microbiology, Munich Municipal Clinic Group, Munich, Germany.

Mads Nybo (M)

Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.

Rubén Gómez Rioja (R)

Laboratory Medicine Department, La Paz University Hospital, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH